Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind study of SYSA1901 versus Perjeta with trastuzumab and docetaxel as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
CTR20222617Phase 3Completed
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jan 2023; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20222617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222617.